Kye Pharmaceuticals Announces Commercial Availability of CORZYNA™ 1000 mg (ranolazine extended-release tablets)

Text provided by
June 1, 2023

Kye Pharmaceuticals Inc. (“Kye”), a private company headquartered in Mississauga, Ontario focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, today announced an important milestone, PrCORZYNA™ (ranolazine extended-release tablets) is now commercially available in a 1000 mg tablet strength.

CORZYNA™ is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (including beta-blockers and calcium antagonists). CORZYNA™ was first available in Spring 2021 exclusively in 500 mg tablets.   As of June 1st 2023,  CORZYNA 1000 mg extended-release tablets are available for Canadian patients.

“Kye is pleased to announce that the CORZYNA™ 1000 mg strength tablet is available in Canada” stated Julian Oliver, Director, Marketing and Business Operations of Kye, “This additional tablet strength will provide more efficient dosing for Canadian patients and healthcare professionals in the treatment of stable angina with CORZYNA™.”

About Stable Angina

Angina is the term for chest pain or chest discomfort. Angina occurs when the heart muscle is not getting enough blood and therefore enough oxygen to work properly. It is usually caused by hardening of the arteries. Chronic angina, the most common symptom of coronary artery disease, can be a debilitating heart condition. Angina typically manifests as recurrent pain or tightness in the chest upon exertion or emotional stress.

About KYE Pharmaceuticals

Kye Pharmaceuticals Inc. (“Kye”) is a private company headquartered in Mississauga, Canada focused on bringing medications to the Canadian market which fulfill clinically significant and unmet needs. KYE has licensed many innovative products and was founded on an entrepreneurial spirit that optimizes our team’s strengths and brings unique value to our partners, Canadian healthcare professionals, and most importantly, patients across Canada. For more information, please visit

Investor Contact
Company Contact
Media Contact
Related Links

You may also like